Aethlon Medical, Inc. has announced that research related to the Aethlon Hemopurifier as a potential treatment for Ebola Hemorrhagic Fever has been initiated at The Centers for Disease Control and Prevention (CDC).

Ebola is classified as a category "A" bioterror threat presently untreatable with antiviral drug and vaccine therapy. According to the World Health Organization, Ebola causes death in 50-90 percent of all clinically ill cases.

San Diego-based Aethlon Medical also said that the scope of these studies has been expanded to include researchers at The United States Army Medical Research Institute of Infectious Diseases (USAMRIID). USAMRIID is the lead medical research laboratory of the U.S. Biological Defense Research Program. The Institute plays a key role as the only laboratory in the Department of Defense equipped to study Ebola and other highly hazardous infectious agents requiring maximum containment at bio-safety level (BLS)-4.